These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37174645)

  • 1. Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial.
    Park CK; Jun HR; Oh HJ; Lee JY; Cho HJ; Kim YC; Lee JE; Yoon SH; Choi CM; Lee JC; Lee SY; Lee SY; Chun SM; Oh IJ
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
    Kim ES; Velcheti V; Mekhail T; Yun C; Shagan SM; Hu S; Chae YK; Leal TA; Dowell JE; Tsai ML; Dakhil CSR; Stella P; Jin Y; Shames DS; Schleifman E; Fabrizio DA; Phan S; Socinski MA
    Nat Med; 2022 May; 28(5):939-945. PubMed ID: 35422531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer.
    Zhang S; Yang L; Yang Y; Xin Y; Wang Y
    Thorac Cancer; 2022 Dec; 13(23):3374-3383. PubMed ID: 36274215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
    Nie W; Wang ZJ; Zhang K; Li B; Cai YR; Wen FC; Zhang D; Bai YZ; Zhang XY; Wang SY; Cheng L; Zhong H; Liu L; Wang J; Han BH
    BMC Med; 2022 May; 20(1):170. PubMed ID: 35509036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
    Si H; Kuziora M; Quinn KJ; Helman E; Ye J; Liu F; Scheuring U; Peters S; Rizvi NA; Brohawn PZ; Ranade K; Higgs BW; Banks KC; Chand VK; Raja R
    Clin Cancer Res; 2021 Mar; 27(6):1631-1640. PubMed ID: 33355200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
    Wang Z; Duan J; Wang G; Zhao J; Xu J; Han J; Zhao Z; Zhao J; Zhu B; Zhuo M; Sun J; Bai H; Wan R; Wang X; Fei K; Wang S; Zhao X; Zhang Y; Huang M; Huang D; Qi C; Gao C; Bai Y; Dong H; Xiong L; Tian Y; Wang D; Xu C; Wang W; Li J; Hu X; Cai S; Wang J
    J Thorac Oncol; 2020 Apr; 15(4):556-567. PubMed ID: 31843683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
    Chen X; Fang L; Zhu Y; Bao Z; Wang Q; Liu R; Sun W; Du H; Lin J; Yu B; Chen S; Zhou J; Zhou J
    Cancer Immunol Immunother; 2021 Dec; 70(12):3513-3524. PubMed ID: 33899131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab.
    Nie W; Qian J; Xu MD; Gu K; Qian FF; Hu MJ; Lu J; Gan L; Zhang XY; Cao SH; Li JW; Wang Y; Zhang B; Wang SY; Hu F; Li CH; Zhong H; Han BH
    Oncoimmunology; 2020; 9(1):1731072. PubMed ID: 32158623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies.
    Chen YT; Seeruttun SR; Wu XY; Wang ZX
    Front Oncol; 2019; 9():1432. PubMed ID: 31921683
    [No Abstract]   [Full Text] [Related]  

  • 12. Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.
    Jiang T; Li X; Wang J; Su C; Han W; Zhao C; Wu F; Gao G; Li W; Chen X; Li J; Zhou F; Zhao J; Cai W; Zhang H; Du B; Zhang J; Ren S; Zhou C; Yu H; Hirsch FR
    Theranostics; 2017; 7(19):4753-4762. PubMed ID: 29187901
    [No Abstract]   [Full Text] [Related]  

  • 13. Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.
    Schuurbiers M; Huang Z; Saelee S; Javey M; de Visser L; van den Broek D; Heuvel MVD; Lovejoy AF; Monkhorst K; Klass D
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
    Peters S; Dziadziuszko R; Morabito A; Felip E; Gadgeel SM; Cheema P; Cobo M; Andric Z; Barrios CH; Yamaguchi M; Dansin E; Danchaivijitr P; Johnson M; Novello S; Mathisen MS; Shagan SM; Schleifman E; Wang J; Yan M; Mocci S; Voong D; Fabrizio DA; Shames DS; Riehl T; Gandara DR; Mok T
    Nat Med; 2022 Sep; 28(9):1831-1839. PubMed ID: 35995953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients.
    Zhou X; Li C; Zhang Z; Li DY; Du J; Ding P; Meng H; Xu H; Li R; Ho E; Zhang A; Okunieff P; Lu J; Sha MY
    Sci Rep; 2021 Apr; 11(1):7633. PubMed ID: 33828112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel.
    Nie W; Qian J; Xu MD; Gu K; Qian FF; Lu J; Zhang XY; Wang HM; Yan B; Zhang B; Wang SY; Hu F; Li CH; Zhong H; Han BH
    J Natl Compr Canc Netw; 2020 May; 18(5):582-589. PubMed ID: 32380463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC.
    Liu M; Xia S; Zhang X; Zhang B; Yan L; Yang M; Ren Y; Guo H; Zhao J
    Lung Cancer; 2022 Aug; 170():148-155. PubMed ID: 35792434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
    Cortellini A; Ricciuti B; Borghaei H; Naqash AR; D'Alessio A; Fulgenzi CAM; Addeo A; Banna GL; Pinato DJ
    Cancer; 2022 Aug; 128(16):3067-3079. PubMed ID: 35727053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
    Gandara DR; Paul SM; Kowanetz M; Schleifman E; Zou W; Li Y; Rittmeyer A; Fehrenbacher L; Otto G; Malboeuf C; Lieber DS; Lipson D; Silterra J; Amler L; Riehl T; Cummings CA; Hegde PS; Sandler A; Ballinger M; Fabrizio D; Mok T; Shames DS
    Nat Med; 2018 Sep; 24(9):1441-1448. PubMed ID: 30082870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.